Abstract
The immunopathogenesis of 25 kindreds affecting 100 males with the X-linked lymphoprolif erative syndrome (XT P) is being studied comprehensively by our registry and laboratory group. XLP is a combined variable immune deficiency with Epstein-Barr virus (EBV) induced phenotypes of: (1) fatal infectious mononucleosis (IM), (2) chronic IM progressive to malignant lymphoma, (3) acute IM progressive to acquired agammaglobulinemia or (4) malignant lymphoma. Cytogenetic studies of peripheral blood lymphocytes from 15 surviving males and 21 carrier females reveal random karyotype errors in several kindreds. Often polyclonal Ig or selective IgM increases and lymphocytosis with plasmacytoid forms typifies the IM phenotypes. Weakly reactive EBV-specific antibodies are found and anti-EB nuclear antigen is lacking. Antibodies to EBV are paradoxically elevated in female carriers. Initially all lymphoid tissues show immunoblastic proliferation with plasma cell differentiation and focal to extensive necrosis. Thymus gland and other lymphoid organs become depleted in T cell regions and Hassall’s corpuscles may become destroyed. Multinucleated giant cells may be seen destroying the corpuscles or calcified corpuscles are found. The lymphoid infiltrates and lesions resemble graft-versus-host response in the fatal IM phenotype. Extensive necrosis in lymph nodes and deficient Ig secretion of B-cells characterize acquired agammaglobulinemia phenotypes. The malignant lymphomas span the spectrum of B cell differentiation with most being immunoblastic sarcomas. One case probably was monoclonal thus far, others are being studied. EBV DNA hybridization of tissues from 7 patients with fatal IM revealed 1 to 20 EBV genome equivalents per cell. The patients lacked appropriate EBV antibody responses. Our studies of XLP support the hypothesis that immune deficiency the EBV permits chronic and fatal lymphoproliferative diseases in XLP following EBV infections. Owing to this knowledge, rational bases for prevention by genetic counseling and by providing high titer gammaglobulin and antiviral therapy is being attempted.
This study was supported in part by a grant from the National Institutes of Health, CA 23561-02
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bausher JC, Smith RT (1973) Studies of the Epstein-Barr virus-host relationship: autochthonous and allogeneic lymphocyte stimulation by lymphoblast cell lines in mixed cell culture. Clin Immunol Immunophathol 1:270–281
Berard C, O’Conor GT, Thomas LB, Torloni H (1979) Histophathological definition of Burkitt’s tumor. Bull WHO 40:601–607
Beverly P, Knight D (1979) News and Views: Killing comes naturally. Nature 278:119–120
Borzy MS, Hong R, Horowitz S et al. (1979) Fatal lymphoma after transplantation of cultured thymus in children with combined immunodeficiency disease. N Engl J Med 301:565–568
Burkitt DP (1958) A sarcoma involving the jaws in African children. Br J Surg 46:218–223
Carter RL (1975) Infectious mononucleosis: Model for self-limiting lymphoproliferation. Lancet 11:846–849
Carter RL, Penman HG (1969) Histopathology of infectious mononucleosis. In: Carter RL, Penman HG (eds) Infectious mononucleosis. Blackwell, Oxford Edinburgh, pp 146–161
Dameshek W, Gunz F (1964) Leukemia. Grune & Stratton, New York, p 556
Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet i: 702–703
Evans AS (1978) Infectious mononucleosis and related syndromes. J Med Sci 276:325–339
Hamilton JK, Paquin LA, Sullivan JL, Maurer HS, Cruzi FG, Privisor AJ, Steuber CP, Hawkins E, Yawn D, Cornet JA, Clausen K, Finkelstein JZ, Landing B, Grunnet M, Purtilo DT (1980) X-linked lymphoproliferative syndrome registry report. J Pediatr 96:669–673
Hanto D, Frizzera G, Purtilo D, Sakamato K, Sullivan JL, Saemundsen AK, Klein G, Simons RL, Najarian JS (1981) Lymphoproliferative disorders in renal transplant recipients. II. A. clinical spectrum and evidence for the role of Epstein-Barr virus. Cancer Res, in press
Haynes B, Schooley RT, Payling-Wright CR, Grouse JE, Dolin R, Fauci AS (1979) Emergence of suppressor cells of Immunoglobulin synthesis during acute infectious mononucleosis. J Immunol 123:2095–2101
Heberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P (1979) Natural killer cells: characteristics and regulation of activity. Immunol Rev 44:43–70
Henle W, Henle G, Horwitz CA (1974) Epstein-Barr virus-specific diagnostic tests in infectious mononucleosis. Human Pathol 5:551–565
Henle G, Lennette ET, Alspaugh MA, Henle W (1979) Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies. Clin Exp Immunol 36:415–422
Horwitz CA, Henle W, Henle G, Schmitz H (1975) Clinical evaluations of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med 58:330–338
Hutt LM, Huang YT, Discomb HE, Pagano LS (1975) Emhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis. J Immunol 115:243–248
Junge U, Hoekstra J, Deinhardt F (1971) Stimulation of peripheral lymphocytes by allogeneic and autochthonous mononucleosis lymphocyte cell lines. J Immunol 106:1306–1315
Klein G (1975) The Epstein-Barr virus and neoplasia N Engl J Med 293:1353–1357
Klein G, Svedmyr E, Jondal M, Person PO (1976) EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer 17:21–26
Klein E, Masucci MG, Masucci G, Vanky F (to be published) Natural and activated lymphocyte killers which affect tumor cells. In: Heberman R (ed) Natural cell-mediated immunity against tumors. Academic, New York
Langhorne J, Feizi T (1977) Studies on heterophile antibodies of infectious mononucleosis. Clin Exp Immunol 30:354–363
McKinney AA, Cline WS (1974) Annotation: infectious mononucleosis. Br J Haematol 27:367
Moss DJ, Pope JH (1975) EB virus-associated nuclear antigen production and cell proliferation in adult peripheral blood leukocytes inoculated with the QIMR-WIL strain of EB virus. Int J Cancer 15:503–511
Moss DJ, Rickinson AB, Pope JH (1978) Long-term T cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 22:662–668
Moss DJ, Rickinson AB, Pope JH (1979) Long-term T cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int J Cancer 23:618–625
Pagano JS, Okasinski GF (1978) Pathogenesis of infectious mononucleosis, Burkitt’s lymphoma and nasopharyngeal carcinoma: a unified scheme. In: de-Thé G, Henle W, Rapp F (eds) Oncogenesis and herpesvirus III. International Agency for Research on Cancer, Lyon, pp 687–697
Papermichael M, Scheldon PJ, Holoboro EG (1974) T & B cell populations in infectious mononucleosis. Clin Exp Immunol 18:1–11
Paquin LA, Maurer HS, Purtilo DT (to be published) Chromosomal abnormalities in the X-linked lymphoproliferative syndrome.
Pattengale PK, Smith RW, Perlin E (1974) Atypical lymphocytes in acute infectious mononucleosis. Identification by multiple T and B lymphocyte markers. N Engl J Med 291:1145–1148
Purtilo DT (1976a) Hypothesis: Pathogenesis and phenotypes of an X-linked lymphoproliferative syndrome. Lancet ii: 883–885
Purtilo DT (1976b) Prevalence of Burkitt’s lymphoma in males. N Engl J Med 295:1484
Purtilo DT (1977) Non-Hodgkin’s lymphoma in the X-linked recessive immunodeficiency and lymphoproliferative syndromes. Semin Oncol 4:335–343
Purtilo DT (1980) Epstein-Barr virus-induced oncogenesis in immune defincient individuals. Lancet i:300–303
Purtilo DT (1980) Immunopathogenesis and complications of infectious mononucleosis. In: Sommers S, Rosen PP (ed) Pathology Annual 1980. Appleton-Century-Crofts pp 253–299
Purtilo DT, Sullivan JL (1979) Immunological bases for superior survival of females. Am J Dis Child 133:1251–1253
Purtilo DT, Cassel C, Yang JPS (1974a) Fatal infectious mononucleosis in familial lymphohistiocytosis. N Engl J Med 291:736
Purtilo DT, Hutt L, Cassel C (1974b) X-linked recessive familial lymphohistiocytosis. Clin Res 22:705A
Purtilo DT, Cassel C, Yang JPS, Stephenson SR, Harper R, Landing BH, Vawter GF (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet i: 935–941
Purtilo DT, DeFlorio D, Hutt LM, Bhawan J, Yang JPS, Otto R, Edwards W, Rosen FS, Vawter G (1977a) Variable phenotypic expression of X-linked recessive lymphoproliferative syndrome. N Engl J Med 297:1077–1081
Purtilo DT, Yang JPH, Allegra S, DeFlorio D, Hutt L (1977b) The pathogenesis and hematopathology of the X-linked recessive lymphoproliferative syndrome. Am J Med 62:225–233
Purtilo DT Bhawan J, DeNicola L et al. (1978a) Epstein-Barr virus infections in a X-linked recessive lymphoproliferative syndrome. Lancet i: 798–802
Purtilo DT, Hutt LM, Allegra S, Cassel C, Yang JPS (1978b) Immunodeficiency to the Epstein-Barr virus in the X-linked recessive lymphoproliferative syndrome. Clin Immunol Immunopathol 9:147–156
Purtilo DT, Paquin LA, Gindhart T (1978c) Genetics of neoplasia: Impact of ecogenetics on oncogenesis. Am J Pathol 91:609–688
Purtilo DT, Hamilton J, Sullivan J, Paquin L, — Bhawan J, Sakamoto K (1979a) Epstein-Barr virus-induced oncogenesis in immunodeficient patients. Lab Invest 40:296
Purtilo DT, Paquin LA, DeFlorio D, Virzi F, Sahkuja T (1979b) Diagnosis and immunopathogenesis of the X-linked recessive lymphoproliferative syndrome. Semin Hematol 16:309–343
Purtilo DT, Sakamoto K, Saemundsen AK, Sullivan JL, Synnerholm A-C, Anvret M, Pritchard J, Seiff C, Pincott J, Pachman L, Rich K, Cruzi F, Cornet JA, Collins R, Barnes N, Knight J, Sandstedt B, Klein G (1981) Documentation of Epstein-Barr virus infection in immunodeficient patients with lifethreatening lymphoproliferative diseases by clinical, virological and immunopathological studies. Cancer Res, in press
Purtilo DT, Sullivan JL, Paquin LA (to be published b) Biomarkers in immunodeficiency syndromes predisposing to cancer. In: Lynch H, Guirgis H (eds) Biological markers in cancer. Van Nostrand, New York
Reedman BM, Klein G (1973) Cellular localizations of an Epstein-Barr vjrus (EBV)-associated complement-fixing antigen in producer and nonproducer lymphoblastoid cell lines. Int J Cancer 11:499–520
Rickinson AB, Moss DJ, Pope JH (1979) Long-term T-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int J Cancer 23:610–617
Rickinson AB, Moss DJ, Pope JH, Ahlberg N (1980) Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patient. Int J Caner 25:59–65
Royston I, Sullivan JL, Penman PO, Perlin E (1976) Cell-mediated immunity in acute infectious mononucleosis. Bibl Haematol 43:278–280
Sakamoto K, Freed H, Purtilo DT (1980) Antibody responses to Epstein-Barr virus in families with the X-linked lymphoproliferative syndrome. J Immunol 125:921–925
Saksela E, Timonen T, Virtanen I, Cantell K (to be published) Regulation of human natural killer activity by interferon. In: Heberman R (ed) Natural cell-mediated immunity against tumors. Academic, New York
Seemayer TA, Lapp WS, Bolande RP (1977) Thymic involution in murine graft-versushost reaction. Am J Pathol 88:119–134
Spector BD, Perry GS, Kersey JH (1978) Genetically determined immunodeficiency diseases (GDID) and malignancy: Report from the Immuno-deficiency-Cancer Registry. Clin Immunol Immunopathol 11:12–29
Stebbing N (1979) Interferons and inducers in vivo. Nature 279:581–582
Steel CM, Hardy DA (1970) Evidence of altered antigenicity in cultured lymphoid cells from patients with infectious mononucleosis. Lancet i: 1322–1323
Sullivan JL, Byron K, Brewster F, Purtillo DT (1980) Deficient natural killer (NK) cell activity in patients with the x-linked lymphoproliferative syndrome. Science 210:543–545
Sutton RNP, Emond TD, Thomas DB, Doniach D (1974) The occurrence of autoantibodies in infectious mononucleosis. Clin Exp Immunol 17:427–436
Svedmyr E, Jondal M (1975) Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 72:1622–1626
Thomas DB (1972) Antibodies to membrane antigens common to thymocytes and a subpopulation of lymphocytes in infectious mononucleosis sera. Lancet i: 399–403
Thorley-Lawson DA (1980) The suppression of Epstein-Barr virus infection in vitro occurs after infection, but before transformation of the cell. J Immunol 124:745–751
Thorley-Lawson DA, Chess L, Strominger JL (1978) Suppression of in vitro Epstein-Barr virus antigens: a new role for adult T lymphocytes. J Exp Med 146:495–508
Tosato G, Magrath I, Koski I, Dooley N, Blaese M (1979) Activation of suppressor T cells during Epstein-Barr virus-induced infectious mononucleosis. N Engl J Med 301:1133–1137
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Purtilo, D.T. (1981). Immunopathology of the X-Linked Lymphoproliferative Syndrome. In: Neth, R., Gallo, R.C., Graf, T., Mannweiler, K., Winkler, K. (eds) Modern Trends in Human Leukemia IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 26. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67984-1_34
Download citation
DOI: https://doi.org/10.1007/978-3-642-67984-1_34
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-10622-7
Online ISBN: 978-3-642-67984-1
eBook Packages: Springer Book Archive